Arbutus Biopharma Corp (ABUS) Stock Score, Valuation & Financial Research
Arbutus Biopharma Corp is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 49/100.
Quick answer for ABUS
Arbutus Biopharma Corp currently has a Wall Street Score of 49/100. The stored market price is $5.12. Its financial score is 25/100. Its valuation score is 71/100. The latest WSS change is +0.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Arbutus Biopharma Corp does
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is
ABUS financial snapshot
- Wall Street Score:
- 49/100
- Current price:
- $5.12
- Market capitalization:
- $1.01B
- Revenue:
- $181.7M
- Net income:
- $153.1M
- Free cash flow:
- $-39.6M
- Cash:
- $19.2M
- Total debt:
- $3.6M
- EPS:
- 0.79
- P/E ratio:
- 6.5x
- Financial score:
- 25/100
- Valuation score:
- 71/100
- Revenue score:
- 57/100
What stands out
- Reported year-over-year revenue growth is +11.9%.
- Free cash flow is $-39.6M, showing cash burn in the current stored period.
- The balance sheet shows $19.2M of cash versus $3.6M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.5 points: ABUS increased 0.5 points because Valuation improved by 8.2 points.
What the numbers mean
Its current valuation score is 71/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ABUS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.